Report Library
All Reports
Q3 2011 BMT Outlook Report
July 11, 2011
Our Q2 2011 report detailed several significant catalysts that resulted in double-digit stock price changes, details of which can be found in the table on Page 2 of this report.
Our Q3 2011 report covers a number of catalysts from 14 drugs and one device. Additionally, we have included comprehensive calendars through September 2011 from our sister product, CatalystTracker, of Large Impact catalysts in the drug, device/diagnostic and natural resource areas.
For the full report, please download the PDF version at the top of this page.
For our disclosures, please read the BioMedTracker Research Standards.
| Indications Covered: |
Acute Coronary Syndrome (ACS)
Anaplastic Large Cell Lymphoma (ALCL) Axial Spondyloarthritis Diabetes Mellitus, Type II Dry Eye Disease HIV / AIDS Treatment Hodgkin's Lymphoma Multiple Sclerosis (MS) Opioid Induced Constipation (OIC) Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH) Rheumatoid Arthritis (RA) Smoking Cessation Stroke Prevention in Atrial Fibrillation (SPAF) Wet Age-Related Macular Degeneration (Wet AMD) |